Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Aeolus cleared to begin phase I trials of AEOL-10150

Sep. 10, 2004

AstraZeneca claims three novel series of delta opioid agonists

Sep. 10, 2004

Cambridge Laboratories acquires U.K. rights to palonosetron

Sep. 9, 2004

Merck researchers develop new macrocyclic BACE inhibitors

Sep. 9, 2004

Novel CGRP antagonists for migraine therapy presented by Boehringer Ingelheim

Sep. 9, 2004

Cymbalta approved for diabetic peripheral neuropathic pain

Sep. 8, 2004

5-HT/norepinephrine reuptake inhibitors and their use in depression, anxiety and pain

Sep. 8, 2004

BIBN-4096BS reveals viability of CGRP receptor antagonism in headache

Sep. 7, 2004

Novel adenosine A2A antagonists and their use in depression, AD, PD, etc.

Sep. 7, 2004

FDA response for Lyrica

Sep. 7, 2004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026